Type-1 polarized dendritic cells loaded with apoptotic prostate cancer cells are potent inducers of CD8+ T cells against prostate cancer cells and defined prostate cancer-specific epitopes

Prostate

Volumn 71, Issue 2, 2011, Pages 125-133

  Wieckowski, Eva ^a   Chatta, Gurkamal S ^b,c   Mailliard, Robbie M ^a   Gooding, William ^d   Palucka, Karolina ^e,f   Banchereau, Jacques ^e,f   Kalinski, Pawel ^a,b,c  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^d UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^e BAYLOR INSTITUTE FOR IMMUNOLOGY RESEARCH   (United States)

^f MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

CTLs; dendritic cells; IL 12; prostate cancer; vaccines

Indexed keywords

ACID PHOSPHATASE PROSTATE ISOENZYME; ADENOSINE 3' PHOSPHATE 5' PHOSPHOSULFATE; DENDRITIC CELL VACCINE; EPITOPE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 12P70; INTERLEUKIN 1BETA; INTERLEUKIN 4; INTERLEUKIN 6; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; POLYINOSINIC POLYCYTIDYLIC ACID; PROSTAGLANDIN E2; TUMOR NECROSIS FACTOR ALPHA;

ANTIGEN SPECIFICITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER IMMUNOTHERAPY; CD8+ T LYMPHOCYTE; CELL MATURATION; CELL STRAIN LNCAP; CONTROLLED STUDY; DENDRITIC CELL; FEASIBILITY STUDY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; MONOCYTE; POLARIZATION; PRIORITY JOURNAL; PROSTATE CANCER; RECURRENT CANCER; T LYMPHOCYTE ACTIVATION; ULTRAVIOLET RADIATION;

ALKALINE PHOSPHATASE; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; DENDRITIC CELLS; EPITOPES, T-LYMPHOCYTE; FLOW CYTOMETRY; HUMANS; IMMUNOTHERAPY, ADOPTIVE; INTERLEUKIN-12; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TH1 CELLS;

EID: 78650992800     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.21228     Document Type: Article

References (42)

1. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer EJ, Thun MJ,. Cancer statistics, 2005. CA Cancer J Clin 2005; 55 (1): 10-30.
2. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ,. Cancer statistics, 2009. CA Cancer J Clin 2009; 59 (4): 225-249.
3. Coen JJ, Zietman AL, Thakral H, Shipley WU,. Radical radiation for localized prostate cancer: Local persistence of disease results in a late wave of metastases. J Clin Oncol 2002; 20 (15): 3199-3205.
4. Roehl KA, Han M, Ramos CG, Antenor JA, Catalona WJ,. Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: Long-term results. J Urol 2004; 172 (3): 910-914.
5. Catalona WJ, Smith DS,. Cancer recurrence and survival rates after anatomic radical retropubic prostatectomy for prostate cancer: Intermediate-term results. J Urol 1998; 160 (6 Pt 2): 2428-2434.
6. Dillioglugil O, Leibman BD, Kattan MW, Seale-Hawkins C, Wheeler TM, Scardino PT,. Hazard rates for progression after radical prostatectomy for clinically localized prostate cancer. Urology 1997; 50 (1): 93-99.
7. Miyamoto H, Messing EM, Chang C,. Androgen deprivation therapy for prostate cancer: Current status and future prospects. Prostate 2004; 61 (4): 332-353.
8. Vogelzang N,. New developments in the treatment of advanced prostate cancer. Semin Oncol 1997; 23 (6 Suppl 14): 1-5.
9. Nouri-Shirazi M, Banchereau J, Bell D, Burkeholder S, Kraus ET, Davoust J, Palucka KA,. Dendritic cells capture killed tumor cells and present their antigens to elicit tumor-specific immune responses. J Immunol 2000; 165 (7): 3797-3803.
10. Meidenbauer N, Harris DT, Spitler LE, Whiteside TL,. Generation of PSA-reactive effector cells after vaccination with a PSA-based vaccine in patients with prostate cancer. Prostate 2000; 43 (2): 88-100.
11. Murphy GP, Tjoa BA, Simmons SJ, Jarisch J, Bowes VA, Ragde H, Rogers M, Elgamal A, Kenny GM, Cobb OE, Ireton RC, Troychak MJ, Salgaller ML, Boynton AL,. Infusion of dendritic cells pulsed with HLA-A2-specific prostate-specific membrane antigen peptides: A phase II prostate cancer vaccine trial involving patients with hormone-refractory metastatic disease. Prostate 1999; 38 (1): 73-78.
12. Murphy GP, Tjoa BA, Simmons SJ, Ragde H, Rogers M, Elgamal A, Kenny GM, Troychak MJ, Salgaller ML, Boynton AL,. Phase II prostate cancer vaccine trial: Report of a study involving 37 patients with disease recurrence following primary treatment. Prostate 1999; 39 (1): 54-59.
13. Tjoa BA, Simmons SJ, Bowes VA, Ragde H, Rogers M, Elgamal A, Kenny GM, Cobb OE, Ireton RC, Troychak MJ, Salgaller ML, Boynton AL, Murphy GP,. Evaluation of phase I/II clinical trials in prostate cancer with dendritic cells and PSMA peptides. Prostate 1998; 36 (1): 39-44.
14. Mincheff M, Tchakarov S, Zoubak S, Loukinov D, Botev C, Altankova I, Georgiev G, Petrov S, Meryman HT,. Naked DNA and adenoviral immunizations for immunotherapy of prostate cancer: A phase I/II clinical trial. Eur Urol 2000; 38 (2): 208-217.
15. Pavlenko M, Roos AK, Lundqvist A, Palmborg A, Miller AM, Ozenci V, Bergman B, Egevad L, Hellstrom M, Kiessling R, Masucci G, Wersall P, Nilsson S, Pisa P,. A phase I trial of DNA vaccination with a plasmid expressing prostate-specific antigen in patients with hormone-refractory prostate cancer. Br J Cancer 2004; 91 (4): 688-694.
16. Sipuleucel-T APC 8015, APC, prostate cancer vaccineâDendreon. Drugs R&D 2006; 7 (3): 197-201.
17. Harzstark AL, Small EJ,. Immunotherapy for prostate cancer using antigen-loaded antigen-presenting cells: APC8015 (Provenge). Expert Opin Biol Ther 2007; 7 (8): 1275-1280.
18. Peshwa MV, Shi JD, Ruegg C, Laus R, van Schooten WC,. Induction of prostate tumor-specific CD8+ cytotoxic T-lymphocytes in vitro using antigen-presenting cells pulsed with prostatic acid phosphatase peptide. Prostate 1998; 36 (2): 129-138.
19. Small EJ, Fratesi P, Reese DM, Strang G, Laus R, Peshwa MV, Valone FH,. Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J Clin Oncol 2000; 18 (23): 3894-3903.
20. Valone FH, Small E, MacKenzie M, Burch P, Lacy M, Peshwa MV, Laus R,. Dendritic cell-based treatment of cancer: Closing in on a cellular therapy. Cancer J 2001; 7 (Suppl 2): S53-S61.
21. Correale P, Walmsley K, Nieroda C, Zaremba S, Zhu M, Schlom J, Tsang KY,. In vitro generation of human cytotoxic T lymphocytes specific for peptides derived from prostate-specific antigen. J Natl Cancer Inst 1997; 89 (4): 293-300.
22. Kobayashi K, Noguchi M, Itoh K, Harada M,. Identification of a prostate-specific membrane antigen-derived peptide capable of eliciting both cellular and humoral immune responses in HLA-A24+ prostate cancer patients. Cancer Sci 2003; 94 (7): 622-627. (Pubitemid 36975018)
23. Machlenkin A, Paz A, Bar Haim E, Goldberger O, Finkel E, Tirosh B, Volovitz I, Vadai E, Lugassy G, Cytron S, Lemonnier F, Tzehoval E, Eisenbach L,. Human CTL epitopes prostatic acid phosphatase-3 and six-transmembrane epithelial antigen of prostate-3 as candidates for prostate cancer immunotherapy. Cancer Res 2005; 65 (14): 6435-6442.
24. Finke LH, Wentworth K, Blumenstein B, Rudolph NS, Levitsky H, Hoos A,. Lessons from randomized phase III studies with active cancer immunotherapiesâOutcomes from the 2006 meeting of the Cancer Vaccine Consortium (CVC). Vaccine 2007; 25 (Suppl 2): B97-B109.
25. So-Rosillo R, Small EJ,. Sipuleucel-T (APC8015) for prostate cancer. Expert Rev Anticancer Ther 2006; 6 (9): 1163-1167.
26. Higano CS, Schellhammer PF, Small EJ, Burch PA, Nemunaitis J, Yuh L, Provost N, Frohlich MW,. Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer 2009; 115 (16): 3670-3679.
27. Kantoff PW, Schuetz TJ, Blumenstein BA, Glode LM, Bilhartz DL, Wyand M, Manson K, Panicali DL, Laus R, Schlom J, Dahut WL, Arlen PM, Gulley JL, Godfrey WR,. Overall survival analysis of a phase II randomized controlled trial of a poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol 2010; 28 (7): 1099-1105.
28. Vieira PL, de Jong EC, Wierenga EA, Kapsenberg ML, Kalinski P,. Development of Th1-inducing capacity in myeloid dendritic cells requires environmental instruction. J Immunol 2000; 164 (9): 4507-4512.
29. Mailliard RB, Wankowicz-Kalinska A, Cai Q, Wesa A, Hilkens CM, Kapsenberg ML, Kirkwood JM, Storkus WJ, Kalinski P,. alpha-type-1 polarized dendritic cells: A novel immunization tool with optimized CTL-inducing activity. Cancer Res 2004; 64 (17): 5934-5937.
30. Lee JJ, Foon KA, Mailliard RB, Muthuswamy R, Kalinski P,. Type 1-polarized dendritic cells loaded with autologous tumor are a potent immunogen against chronic lymphocytic leukemia. J Leukoc Biol 2008; 84 (1): 310-325.
31. Watchmaker P, Urban J, Berk E, Nakamura Y, Mailliard RB, Watkins SC, Van Ham SM, Kalinski P,. Memory CD8+ T cells protect dendritic cells from CTL killing. J Immunol 2008; 180: 3857-3865.
32. Troy A, Davidson P, Atkinson C, Hart D,. Phenotypic characterisation of the dendritic cell infiltrate in prostate cancer. J Urol 1998; 160 (1): 214-219.
33. Aalamian M, Pirtskhalaishvili G, Nunez A, Esche C, Shurin GV, Huland E, Huland H, Shurin MR,. Human prostate cancer regulates generation and maturation of monocyte-derived dendritic cells. Prostate 2001; 46 (1): 68-75. (Pubitemid 32157778)
34. Shurin GV, Aalamian M, Pirtskhalaishvili G, Bykovskaia S, Huland E, Huland H, Shurin MR,. Human prostate cancer blocks the generation of dendritic cells from CD34+ hematopoietic progenitors. Eur Urol 2001; 39 (Suppl 4): 37-40. (Pubitemid 32429656)
35. Kalinski P, Schuitemaker JH, Hilkens CM, Wierenga EA, Kapsenberg ML,. Final maturation of dendritic cells is associated with impaired responsiveness to IFN-gamma and to bacterial IL-12 inducers: Decreased ability of mature dendritic cells to produce IL-12 during the interaction with Th cells. J Immunol 1999; 162 (6): 3231-3236.
36. Langenkamp A, Messi M, Lanzavecchia A, Sallusto F,. Kinetics of dendritic cell activation: Impact on priming of TH1, TH2 and nonpolarized T cells. Nat Immunol 2000; 1 (4): 311-316.
37. Watchmaker PB, Berk E, Muthuswamy R, Mailliard RB, Urban JA, Kirkwood JM, Kalinski P,. Independent regulation of chemokine responsiveness and cytolytic function versus CD8+ T cell expansion by dendritic cells. J Immunol 2010; 184 (2): 591-597.
38. Copier J, Dalgleish A,. Whole-cell vaccines: A failure or a success waiting to happen? Curr Opin Mol Ther 2010; 12 (1): 14-20.
39. Urba WJ, Nemunaitis J, Marshall F, Smith DC, Hege KM, Ma J, Nguyen M, Small EJ,. Treatment of biochemical recurrence of prostate cancer with granulocyte-macrophage colony-stimulating factor secreting, allogeneic, cellular immunotherapy. J Urol 2008; 180 (5): 2011-2017; discussion 2017-2018.
40. Muthuswamy R, Urban J, Lee JJ, Reinhart TA, Bartlett D, Kalinski P,. Ability of mature dendritic cells to interact with regulatory T cells is imprinted during maturation. Cancer Res 2008; 68 (14): 5972-5978.
41. Miller AM, Pisa P,. Tumor escape mechanisms in prostate cancer. Cancer Immunol Immunother 2007; 56 (1): 81-87.
42. Koh YT, Gray A, Higgins SA, Hubby B, Kast WM,. Androgen ablation augments prostate cancer vaccine immunogenicity only when applied after immunization. Prostate 2009; 69 (6): 571-584.